Vis enkel innførsel

dc.contributor.authorSundstrøm, Steinnb_NO
dc.date.accessioned2014-12-19T14:17:50Z
dc.date.available2014-12-19T14:17:50Z
dc.date.created2008-02-29nb_NO
dc.date.issued2006nb_NO
dc.identifier123673nb_NO
dc.identifier.isbn82-471-7827-3nb_NO
dc.identifier.urihttp://hdl.handle.net/11250/263329
dc.languageengnb_NO
dc.publisherDet medisinske fakultetnb_NO
dc.relation.ispartofseriesDoktoravhandlinger ved NTNU, 1503-8181; 2006:42nb_NO
dc.relation.haspartSundstrøm, Stein; Bremnes, Roy M; Kaasa, Stein; Aasebø, Ulf; Hatlevoll, Reidulv; Dahle, Ragnar; Boye, Nils; Wang, Mari; Vigander, Tor; Vilsvik, Jan; Skovlund, Eva; Hannisdal, Einar; Aamdal, Steinar. Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-Up. Journal of Clinical Oncology. 20(24): 4665-4672, 2002.nb_NO
dc.relation.haspartSundstrøm, Stein; Bremnes, Roy M; Kaasa, Stein; Aasebø, Ulf; Aamdal, Steinar. Second-line chemotherapy in recurrent small cell lung cancerResults from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Lung Cancer. 48(2): 251-261, 2005.nb_NO
dc.relation.haspartSundstrøm, Stein; Bremnes, Roy M; Aasebø, Ulf; Aamdal, Steinar; Hatlevoll, Reidulv; Brunsvig, Paal; Johannessen, Dag Clement; Klepp, Olbjørn; Fayvers, Peter M; Kaasa, Stein. Hypofractionated Palliative Radiotherapy (17 Gy per two fractions) in Advanced Non–Small-Cell Lung Carcinoma Is Comparable to Standard Fractionation for Symptom Control and Survival. Journal of Clinical Oncology. 22(5): 765-768, 2004.nb_NO
dc.relation.haspartSundstrøm, Stein; Bremnes, Roy M; Brunsvig, Paal; Aasebø, Ulf; Klepp, Olbjørn; Fayvers, Peter M; Kaasa, Stein. Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)?. Radiotherapy and Oncology. 75(2): 141-148, 2005.nb_NO
dc.titleImproving treatment in patients with lung cancer: Results from two multicentre randomised studiesnb_NO
dc.typeDoctoral thesisnb_NO
dc.contributor.departmentNorges teknisk-naturvitenskapelige universitet, Det medisinske fakultet, Institutt for kreftforskning og molekylær medisinnb_NO
dc.description.degreePhD i klinisk medisinnb_NO


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel